ACC 2022 – Complete Trial QoL: Complete Revascularization in STEMI

The COMPLETE study has shown complete revascularization in STEMI reduces cardiovascular mortality or new AMI, which generated a change in ACC/AHA 2021 revascularization guidelines. However, its impact on quality of life is yet to be studied. 

ACC 2022 - Estudio Complete Trial QoL: Revascularización completa en el SCACEST

The aim of this prespecified analysis of the COMPLETE study is to determine whether complete revascularization improves quality of life free from angina compared against a culprit-only revascularization strategy.

The Seattle Angina Questionnaire (SAQ) was used at randomization, 6 months and final visit (mean 3 years). Assessed outcomes included angina related and proportion of patients free from angina events. 

In STEMI patients with multivessel disease both patients with complete revascularization and culprit only revascularization improved angina related quality of life. At 3-year followup, there was a higher proportion of patients free from angina in the complete revascularization group, with NNT 31 patients.

Read also: ACC 2022 | VALOR-HCM: Mavacamten in Adults with Symptomatic Obstructive HCM Eligible for Septal Reduction Therapy

The subgroup analysis showed the greatest impact: benefit was confined to those with a non-culprit lesion ≥80%.

Conclusions

Complete revascularization in STEMI improves quality of life free from angina compared against culprit only revascularization, a benefit that adds to the one previously showed, the reduction of major cardiovascular events. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board, SOLACI.org

Original Title: Complete trail Qol: Complete trail Quality of life  

Reference: Presentado por Dr. Shamir R. Mehta en las sesiones cientificas anuales del American College of Cardiology (ACC 2022), Washington, Abril 2, 2022.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

QFR vs. FFR: Is Coronary Revascularization Deferral Safe? Results from a FAVOR III Sub-Analysis

In cases of intermediate coronary lesions, functional assessment is recommended to aid the decision-making process regarding revascularization. There are several tools currently used to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...